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Abstract
Vaccines represent one of the greatest achievements of science and medicine in the ﬁght against infectious diseases. Vaccination is one of
the most cost-effective public health tools to prevent infectious diseases. Signiﬁcant progress has been made in expanding the coverage of
vaccines globally, resulting in the prevention of more than two million deaths annually. In 2010, nearly 200 countries endorsed a shared
vision to extend the beneﬁts of vaccines to every person by 2020, known as the Decade of Vaccine Initiative (DoV). Vaccine manufacturers
in developing countries, as represented by the Developing Countries Vaccine Manufacturers Network (DCVMN), make a signiﬁcant
contribution to DoV by supplying quality vaccines at affordable prices to the people who need them most. About 70% of the global
Expanded Program on Immunization (EPI) vaccine supplies are met by DCVMN. Besides EPI vaccine supplies, DCVMN is also targeting
vaccines against rotavirus, Japanese encephalitis, pneumonia, human papillomavirus, meningitis and neglected tropical diseases. This article
reviews the roles and contributions of DCVMN in making the vaccines accessible and affordable to all.
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Introduction
The last decade saw signiﬁcant advances in developing, intro-
ducing and expanding the reach of vaccines globally. More
people than ever before were vaccinated, resulting in signiﬁcant
achievements, including the near eradication of polio and
signiﬁcant reductions in deaths caused by vaccine-preventable
diseases (diphtheria, measles, neonatal tetanus, pertussis).
Around 2 million deaths among children under 5 years of age
are prevented annually despite an increase in birth cohorts
every year [1]. Further, increasingly sophisticated vaccines,
including pneumococcal conjugate vaccine and rotavirus and
human papillomavirus (HPV) vaccines, were rolled out globally
[2]. The vaccine industry based in the developed world (as
represented by the International Federation of Pharmaceutical
Manufacturers Association) and developing countries (repre-
sented by the Developing Countries Vaccine Manufacturers
Network, DCVMN) plays a signiﬁcant role in the achievement
of global immunization targets. The International Federation of
Pharmaceutical Manufacturers Association contributed with
research and development of newer vaccines and DCVMN
played a crucial role in supplying the required quantities of
Expanded Program on Immunization (EPI) vaccines at affordable
prices, which resulted in more vaccine coverage and universal
accessibility of EPI vaccines [3]. In 2010, nearly 200 countries
endorsed a shared global health vision known as the Decade of
Vaccine Initiative (DoV) (2010–2020) with the overall aim of
increasing vaccine coverage in developing countries to 90% to
prevent the deaths of around 7.6 million children under 5 years
of age [4]. The vaccine industry in developed and developing
countries will play a signiﬁcant role in these initiatives. This
article provides an account of the roles and contributions of
DCVMN in increasing access to basic childhood vaccines and of
their contributions to the ﬁght against pandemic and regional
infectious diseases.
This review is a qualitative case study analysis based on
published literature reports and the authors’ experience in the
domain. This article summarizes the trends observed in the
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global market, especially after the manufacturers from the
developing countries started supplying their vaccines to United
Nations (UN) agencies after getting them prequaliﬁed by
WHO. This had a tremendous impact, especially in the
developing countries where these vaccines were introduced,
through the availability both of cheaper vaccines and of newer
vaccines at an early date after their introduction in the
developed world. This especially includes the combination
vaccines containing diphtheria/tetanus/pertussis (DTP), e.g.
DTP-hepatitis B, DTP-Haemophilus inﬂuenzae type B (Hib),
DTP-hepatitis B-Hib; and also vaccines containing measles, e.g.
measles, measles–rubella, measles–mumps–rubella. The recent
example of introduction of meningococcal A conjugate vaccine
(MenAfriVacTM) in the Sub-Saharan Africa meningitis belt is a
classic example of this success story. In addition to this, the
progress made by the developing countries vaccine manufac-
turers for developing vaccines against pandemic inﬂuenza and
seasonal inﬂuenza is a great example, which not only made these
vaccines available, but also increased global capacity for making
inﬂuenza vaccine (both seasonal and pandemic) in the develop-
ing world, which could be harnessed in future pandemics.
Global Vaccine Business: Growth in
Developed, Emerging Markets and UN
Agencies Procurements
The global vaccines market was estimated at around
US$ 32.05 billion in 2012. The market witnessed growth rates
of above 8% and is expected to reach US$ 84.44 billion by
2022 [5]. The increase in sales has been the result of new
product introductions and rising usage, particularly in South
America, Europe, India and China. North America leads the
market with a share of >40%, followed by Europe with 32%
and the developing world with a share of around 20%. The
developed markets represent 15% of the total global popula-
tion but contribute 82% of total sales in value, which is
attributed to high vaccination rates and the launch of newer
vaccines.
The emerging markets in India, China, Brazil, Russian
Federation, Republic of Korea, and Turkey recorded double
digit growth rates in 2012 vaccine sales and are anticipated to
become larger than the developed markets by 2020 [6]. For
instance, the markets in India and China, with rapidly
expanding pharmaceutical and biotechnology industries, are
expected to reach US$ 2.7 billion and US$ 3.1 billion,
respectively, in 2015. Similarly, the South America vaccine
market is expected to rise by 10.0% per year to reach US$ 2.7
billion in 2015. Key factors driving growth for human vaccines
in emerging markets include signiﬁcant unmet medical needs,
and the increased funding support from government and
non-government international agencies for the development
and introduction of new vaccines in the developing world. The
UN Educational, Scientiﬁc and Cultural Organization (UNE-
SCO) science report in 2010 shows that the emerging markets
of China, India and Brazil are by many indications leading most
of the world in the pace of scientiﬁc and technological
developments [7].
Supplies through the UN Vaccine division cater to around
36% of the world’s children as part of its commitment to
improving child survival. In 2012, the UN Children’s Fund
(UNICEF) procured around 1.9 billion doses of vaccines,
including polio, measles, tetanus, bacillus Calmette–Guerin and
yellow fever, at a value of $ 1053 million, which constitutes
around 4–7% of the total vaccine market in value [8]. About 75%
of vaccines currently procured by UN agencies are produced by
manufacturers in developing countries, represented by
DCVMN.
The last decade also saw signiﬁcant growth in the capabil-
ities of suppliers and vaccine manufacturers located in
emerging markets. These manufacturers have historically been
more focused on UN, Global Alliance for Vaccines and
Immunization (GAVI) and WHO markets in the developing
world, and are now increasing their product pipelines with
newer innovative vaccines to target other markets. The recent
acquisition of Bilthoven Biologicals in the Netherlands (sole
supplier of inactivated polio vaccines) by one DCVMN
member, the Serum Institute of India Ltd, Pune, has allowed
the Serum Institute to target markets relevant to polio and
combination vaccines with inactivated polio vaccine in both the
developing and developed world. In another instance, Shantha
Biotech (an ex-member of DCVMN) was acquired by Sanoﬁ
Aventis to tap the strengths of Shantha Biotech and manufac-
ture quality affordable vaccines, which further demonstrates
the attractiveness of emerging markets [9].
DCVMN: a Public Health Driven Alliance to
Develop Affordable Vaccines
DCVMN was established in 2000 with the vision and mission
of increasing the availability and affordability of quality vaccines
to protect against known and emerging infectious diseases. It
largely supplies vaccines to UN agencies. Historically, vaccine
manufacturers based in developed countries have supplied the
majority of prequaliﬁed vaccines for all countries. During
recent years, developed country manufacturers have shown
declining interest in EPI supplies and have increasingly focused
their production on vaccines that are primarily used in
developed countries. As a result of this, the role of developing
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country manufacturers in ensuring the global UN supplies of
EPI vaccines has become important. Vaccines supplied to UN
agencies must be prequaliﬁed for consideration in the tenders.
The prequaliﬁcation process is devised and determined by
WHO. The manufacturers satisfying certain strict norms of
quality, safety and efﬁcacy are prequaliﬁed by WHO and listed
on the WHO website [10]. The ﬁrst products developed by
developing countries were prequaliﬁed for supplies to UN
agencies in 1994. Since then, the process has continued, with
more products from DCVMN being prequaliﬁed every year.
Such prequaliﬁed and other vaccine manufacturers in devel-
oping countries are represented by DCVMN (Tables 1 and 2).
As of October 2013, DCVMN has 39 members in 15 countries
in Latin America, the Middle East, Africa and the Asia Paciﬁc
Region [3,11].
The DCVMN has consistently worked since its inception (in
2000) towards strengthening the capacity of manufacturers to
supply high-quality vaccines. They have contributed >30
vaccine types in various presentations that have been prequal-
iﬁed by WHO for immunization programmes around the
world. DCVMN is now a major supplier to UN agencies and
represents 75% of total procurement volume and around 50%
of value in 2012. Additionally, DCVMN members were among
the top ten suppliers of Pan American Health Organization
(PAHO) supplies in 2012 [12]. DCVMN supplies also helped
GAVI in its efforts to immunize an additional 370 million
children since 2001, which is reported to have prevented >5.5
million future deaths from hepatitis B, Hib, measles, pertussis,
polio, rotavirus diarrhoea and yellow fever. In 2012, 50% of
GAVI vaccine suppliers were DCVMN members [13].
Considering research and development capabilities,
DCVMN members have >45 products in the pipeline. Also,
the ﬁrst prequaliﬁed Japanese encephalitis vaccine was made
available by DCVMN for global procurement in 2013. DCVMN
work on other vaccines, e.g. rotavirus, pneumococcal and HPV
vaccines, is ongoing and the DCVMN members are likely to
launch them at affordable prices (Table 3) [14].
The emergence of DCVMN is an excellent example of a
partnership model wherein organizations such as WHO,
UNICEF, the Bill & Melinda Gates Foundation, donor govern-
ments, the Program for Appropriate Technology in Health
(PATH), national regulatory agencies and national govern-
ments have played a signiﬁcant role in building the capacity of
the vaccine industry in developing countries.
TABLE 1. List of Developing Countries Vaccine Manufactur-
ers Network members by country. There are a total of 39
members spread over 15 different countries; 12 members are
WHO prequaliﬁed, which are indicated in bold
Country Vaccine manufacturer
Argentina National Administration of Laboratories and
Institute of Health Anlis Dr Carlos G. Malbran
Bangladesh Incepta Vaccine limited
Brazil BioManguinhos/Fiocruz
Instituto Butantan
China Beijing Minhai Biotechnology Co., Ltd
Changchun BCHT Biotechnology Co.
China National Biotech Corporation
Hualan Bio
Liaoning ChengDa Biotechnology Co., Ltd
Sinergium Biotech
Sinovac
TiantanBio
Walvax Biotechnology Co., Ltd
Xiamen Innovax Biotech Co., Ltd
Cuba Finlay Institute
The Center for Genetic Engineering and Biotechnology
Egypt Vacsera
India Bharat Biotech International Limited
Cadilla Pharmaceuticals
Biological E Ltd
Haffkine Bio-Pharmaceutical Corporation Ltd
Indian Immunologicals Ltd
Panacea Biotec Limited
Serum Institute of India Ltd
Indonesia Bio Farma
Iran Razi Vaccine & Serum Research Institute
Pasteur Institute of Iran
Korea Greencross Corporation
EuBiologics Co., Ltd
LG Life Sciences
SK Chemicals
Mexico Birmax
South Africa Biovac
Taiwan The National Institute of Infectious Diseases and Vaccinology
Thailand BioNet-Asia Co., Ltd
Queen Saovabha Memorial Institute
The Government Pharmaceutical Organization
Vietnam Institute of Vaccines and Medical Biologicals
Vabiotech
TABLE 2. WHO Prequaliﬁed Vaccines available from Devel-
oping Countries Vaccine Manufacturers Network (DCVMN).
Source WHO website (accessed on 1 November 2013).
Name of DCVMN
member WHO prequaliﬁed vaccines
1. Bio Farma/Indonesia TT, DT, Td, DTwP, Hep B, DTwP-Hep B,
Measles, mOPV, bOPV, tOPV
2. Biological-E/India TT, DTwP-Hep B-Hib, JE
3. BioManguinhos/Fiocruz/Brazil YF, Men. A + C
4. The Centre for Genetic
Engineering and
Biotechnology/Cuba
Hep B, Hib
5. Chengdu Institute/China JE
6. Green Cross Corpn./Korea Seasonal and Inﬂuenza A (H1N1)—
Pandemic Inﬂuenza vaccines
7. The Government
Pharmaceutical Organization/
Thailand
Measles
8. Haffkine Institute/Mumbai mOPV, bOPV, tOPV
9. The Pasteur Institute, Dakar YF
10. Serum Institute of India TT, DT, Td, DTwP, Hep B, BCG, Hib,
Measles, Rubella, MR, MMR,
Meningococcal conjugate vaccine
against serotype A, H1N1 Pandemic
Inﬂuenza, bOPV, tOPV, DTwP-Hep B,
DTwP-Hib, DTwP-Hep B-Hib
11. LG Life Sciences/South Korea Hep-B, DTwP-Hep B-Hib
12. Panacea Biotech, India DTwP-Hep B-Hib
Abbreviations: Upper-case letters denote full-strength doses of diphtheria (D) and
tetanus (T) toxoids and pertussis (P) vaccine. Lower-case ‘d’ denotes reduced
doses of diphtheria used in the adolescent/adult-formulations. Hep B, hepatitis B
vaccine; Hib, Haemophilus inﬂuenzae type b vaccine; wP, whole cell pertussis
vaccine; DTwP-HepB, DTwP-Hib or DTP-HepB-Hib, DTwP-based combination
vaccines containing Hep B or Hib or both antigens; OPV, oral polio vaccine;
mOPV, monovalent oral polio vaccines; bOPV, bivalent oral polio vaccine; tOPV,
trivalent oral polio vaccine; IPV, inactivated polio vaccine; YF, yellow fever; JE,
Japanese encephalitis vaccine; MMR, combination vaccine containing measles,
mumps and rubella antigens.
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The case studies that follow highlight the achievements of
DCVMN in facilitating important milestones of global health.
Case Studies
DCVMN and the Measles & Rubella Initiative
The Measles & Rubella (MR) Initiative is a global partnership
committed to eliminate measles, rubella and other associated
syndromes such as congenital rubella syndrome (CRS) from
the globe. Founded originally as the Measles Initiative in 2001,
it is led by the American Red Cross, the UN Foundation,
UNICEF, the US CDC (Atlanta, GA, USA) and WHO. Since
2001 the initiative has facilitated the delivery of more than 1
billion doses of measles vaccine in more than 60 developing
countries leading to 85% measles vaccination coverage and
74% reduction of measles deaths globally [15]. These efforts
have contributed signiﬁcantly to a reduction in overall child
mortality, as per Millennium Development Goal 4.
Members of DCVMN played an important role in supplying
vaccines to the MR Initiative. It is worth noting that the bulk of
the measles vaccine supplies to the MR Initiative was by a sole
DCVMN supplier, Serum Institute of India Ltd (70% of
supplies), which is now the world’s largest manufacturer of
MMR group vaccines.
DCVMN and eradication of rubella and CRS in the WHO
region of the Americas
PAHO adopted a resolution in 1993 calling for the elimination
of rubella and CRS in the Americas by 2010. Elimination was
deﬁned as the interruption of endemic rubella virus transmis-
sion in all countries of North America, Central America,
South America and the Caribbean for >12 months and no
occurrence of CRS cases attributed to endemic transmission.
To accomplish this goal, PAHO developed a strategy of
introducing rubella-containing vaccine into the routine vacci-
nation programmes of all countries for children aged
12 months and reaching ≥95% coverage in all municipalities.
It was decided to use MR vaccine in this campaign based on
beneﬁt, and risks versus price. From 1998 to 2005, vaccination
campaigns were carried out in Chile, Brazil, Costa Rica,
Honduras, Ecuador and El Salvador; another 18 countries
were added in subsequent years. The campaigns had a huge
impact on measles as well as preventing the re-establishment
of endemic measles virus transmission in the region [16].
A consistent supply of vaccine was ensured by the DCVMN
member, the Serum Institute of India, to whom PAHO later
extended a special award. This vaccination effort led to
eradication of rubella in the Americas, with the last endemic
case observed in February 2009, which was 10 months before
the target. It is reported that beginning in 2001, over a 15-year
period the rubella and CRS initiative will have saved an
estimated US$ 3 billion by preventing >112 500 CRS cases in
Latin America and the Caribbean. The eradication of rubella in
the Americas is also an excellent example of pull mechanisms
for accelerated immunizations. With the notable success of the
MR initiative and rubella elimination in the WHO region of the
Americas, the MR Initiative launched a new Global Measles
and Rubella Strategic Plan in 2012 that includes goals for
reduction of global measles deaths by at least 95% compared
with 2000 levels, and for achieving regional MR/CRS elimina-
tion. Manufacturing capacities of DCVMN will be important for
Global Measles and Rubella and the Strategic Plan [17].
TABLE 3. Developing Countries Vaccine Manufacturers
Network (DCVMN) and future pipeline of vaccines. This list
is based on details given in ref. [27]
Vaccines
DCVMN
manufacturer Country Comments
Pneumococcal
conjugate
BioManguinhos/GSK Brazil Under development
Chengdu Institute/
PATH
China
SII, India/PATH India
Finlay Institute Cuba
Rotavirus Serum Institute of
India
India Phase-3
Instituto Butantan Brazil Phase-2
China National
Biotech Group
China Under development
Biological Evans India Under development
Meningococcal
vaccines (Includes
polysaccharide
and conjugate
vaccines)
Biological Evans India Under development
China National
Biotech Group
China Under development
Finlay Cuba Under development
Serum Institute of
India Ltd
India Under development
Panacea Biotech India Under development
BioManguinhos Brazil Under development
Japanese
encephalitis
vaccine
Vabiotech Vietnam Under development
Bharat Biotech India Phase 3
Indian Immunologicals India Under development
Panacea Biotech India Under development
Seasonal and
Pandemic
inﬂuenza
vaccines (also
includes vaccines
with oil in water
adjuvants)
Vabiotech Vietnam Under development
GPO Thailand Phase III
IVAC Vietnam Under development
Butantan Brazil Phase I/II (new
adjuvant)
Chinese National
Biotech Grp
China Under development
Birmax Mexico Under development
BioManguinhos Brazil Under development
Malaria vaccine Bharat Biotech India Under development
Typhoid vaccine Finlay Institute Cuba Under development
Dengue vaccine Biological Evans India Under development
BioManguinhos/Bionet Brazil
Yellow fever ANLIS Argentina Phase III
Hepatitis A BioManguinhos Brazil Under development
Leishmaniases BioManguinhos Brazil Under development
Leptospirosis BioManguinhos Brazil Under development
Human
papillomavirus
vaccine
Serum Institiute India Under development
CCGEB Cuba Under development
Innovax China Under development
Indian Immunologicals India Under development
Chikungaya Indian Immunologicals India Under development
Anthrax vaccine Panacea Biotech India Phase III
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DCVMN and supply of pentavalent vaccines
The development and uptake of pentavalent vaccines against
ﬁve diseases—diphtheria, tetanus, pertussis, Hib and hepatitis
B—represents the most important cornerstone of this decade.
DCVMN is a major partner to this initiative, which was
launched by the GAVI alliance and aims to achieve maximum
coverage of pentavalent vaccines. GAVI pentavalent demand
from 2013 to 2016 is c.750 million doses, representing c.84%
of the global pentavalent volume, 81% of the global pentavalent
value, and 63% of the global DTP value [18]. Over 70% of
current GAVI/UNICEF pentavalent supplies are met by
DCVMN members based in India. This has also resulted in
pricing innovation wherein the price of the pentavalent vaccine
has dropped by 66% in the last 6 years, moving from US$ 3.60
in 2006 to US$ 1.19 (ten-dose presentation quoted by one
DCVMN member) in 2013.
Global Polio Eradication Initiative and DCVMN
In the last decade, the Global Polio Eradication Initiative
achieved great progress. The best indicator for this achieve-
ment is the eradication of polio from India, which was at one
time termed a world epicentre of polio cases [19,20]. This
achievement would not have been possible without the
consistent and timely supplies of oral polio vaccines (OPV)
by DCVMN members. In this initiative the DCVMN member
Panacea Biotech, India, contributed 9.2 billion doses of OPV
over two decades (1990–2011). Other members of the
network, Bharat Biotech and Haffkine, based in India also
each contributed about 1.5 billion doses since 2006. The world
is now looking towards the introduction of IPV vaccines as a
measure to interrupt polio virus transmission and an increase
in global production capacities for IPV is envisaged. DCVMN
members are already taking steps to increase production
capacities. The development of IPV vaccines will also involve
dose-sparing approaches, such as the use of adjuvants or
process innovations to further increase production capacities
or reduce vaccine costs [21,22].
DCVMN and ﬁght against regional epidemics
Vaccine manufacturers in DCVMN have also accelerated their
efforts in undertaking development and production of innova-
tive vaccines. The DCVMN research and development product
pipeline currently houses 100 projects, of which 15 target new
antigens in the area of regional diseases. One of the major
highlights is the recent development of a polysaccharide
conjugate vaccine against group A meningitis, which has been
responsible for causing recurring epidemics in the meningitis
belt of Sub-Saharan Africa with a population of 300 million. In
2001, it became apparent that no developed country manu-
facturer was ready to develop or supply this vaccine at an
affordable price of <50 cents/dose. The Serum Institute of
India Ltd, a DCVMN member, was approached for develop-
ment of this vaccine through partnerships with the Meningitis
Vaccine project, PATH, WHO and the Center for Biologics
Evaluation and Research, USA (CBER) [23,24]. The vaccine
was licensed and prequaliﬁed in 2010 and within 6 months of
vaccine introduction in Burkina Faso, Mali and Niger, only four
cases of meningitis A were reported, compared with 250 000
cases and 25 000 deaths in the worst ever epidemic in the year
1996–1997 [25,26]. By the end of 2012, more than 100 million
people were vaccinated in ten countries in Africa and it has
been reported that vaccination resulted in a 94% drop in rate
of incidence during the meningitis season. Furthermore, no
cases of serogroup A meningococcal meningitis were detected
in the three vaccinated regions. This is reported as one of
most signiﬁcant outcomes from public health interventions.
Other innovation highlights from DCVMN in the ﬁght
against regional threats are the development and recent
approval of the world’s ﬁrst hepatitis E vaccine, which was
jointly developed by Xiamen Innovax Biotech and the China
National Institute of Diagnostics and Vaccine Development in
Infectious Diseases. As per WHO estimates, over three
million cases of hepatitis E are reported every year. Xiamen
Innovax, a member of DCVMN, is also developing HPV
vaccines using virus-like-particle-based approaches [27].
Another achievement of DCVMN in the ﬁght against
regional threats has been the development, licensing and
WHO prequaliﬁcation of Japanese encephalitis vaccine by
DCVMNmembers Biological Evans, India and Chengdou, China
in 2013. It is expected that the availability of WHO prequaliﬁed
vaccines from DCVMN members will increase global access to
this vaccine. In yet another signiﬁcant development, the launch
of rotavirus and typhoid vaccines by Bharat Biotech, India
further supports the DCVMN potential to undertake develop-
ment and licensing of sophisticated vaccines.
DCVMN and the ﬁght against pandemic threats of global
importance
An effort to ensure global access to pandemic inﬂuenza vaccine
and to increase the global vaccine production capacity of
inﬂuenza vaccines was launched by WHO in 2006–2009 [28].
DCVMN responded to this initiative positively and member
manufacturers developed pilot capacities to develop seasonal
inﬂuenza vaccines until 2008 [29]. In 2009, the inﬂuenza A
(H1N1) virus pandemic threat was detected and issues related
to access, supply and affordability were highlighted and a call
was issued globally to produce the vaccine. It is noteworthy
that three DCVMN members from India readied the vaccine
for global use in a record time of 9 months [30]. The vaccine
was used globally in the ﬁght against pandemic inﬂuenza. This
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constitutes an interesting example wherein DCVMN members
showed maturity and capacity to undertake vaccine develop-
ment in the case of future pandemics [31]. One of the
DCVMN members also obtained WHO prequaliﬁcation for its
intranasal and injectable inactivated inﬂuenza vaccine in 2013.
Discussions and Perspectives for the Future
Members of DCVMN have played a major role in supplying
quality vaccines at affordable prices to UN agencies. The
previous sections provide an overview of the contributions of
DCVMN towards reliable and consistent vaccine supplies.
Clearly, vaccines against diseases such as polio, measles,
rubella, diphtheria, tetanus and pertussis have a signiﬁcant
impact on reduction of deaths in children under 5 years of age.
DCVMN members have taken demonstrable steps towards
developing production capacities for basic EPI vaccines, which
is also evident from the fact that WHO prequaliﬁed vaccine
manufacturers in DCVMN have nearly doubled in the last
decade. The manufacturers followed approaches of build or
buy (ﬁll or ﬁnish), or partner-based approaches to meet these
supplies, e.g. availability of OPV bulk from PT BioFarma
(Bandung, Indonesia) to other DCVMN members resulted in
not only meeting demand for OPV in countries’ immunization
programmes but also WHO Pulse polio programmes towards
the eradication of polio. The case studies of measles, rubella
and polio are the best examples of DCVMN achievements in
meeting global EPI supplies. The production capacities of
DCVMN for EPI vaccines are expected to play a signiﬁcant role
in DoV objectives of further increasing the coverage of
measles, polio, rubella and DTP vaccines in resource-poor
countries. These achievements of DCVMN are also attributed
to the support partner organizations such as WHO, Nether-
lands Vaccine Institute, UNICEF, PAHO, Bill & Melinda Gates
Foundation, PATH, National Institute for Biological Standards
and Control (NIBSC), CDC Atlanta, Sabin Vaccine Institute
and CBER, which led to capacity building of member manu-
facturers [32,33]. The network itself has strengthened the
capacity of manufacturers by facilitating information sharing,
encouraging technology transfer activities and representing the
manufacturers at various international forums.
Technology transfer is the process of sharing skills, knowl-
edge, technologies, methods of manufacturing and facilities
among companies, governments and other institutions to
ensure that the scientiﬁc and technological developments are
accessible to a wide range of users. Technology transfers
played an important role in capacity building of developing
county manufacturers towards the supply of Hib, inﬂuenza and
meningococcal conjugate vaccines [34,35]. It is important to
note that not every emerging manufacturer is a candidate for
such technology transfers. The recipient should have the
scientiﬁc capacity to facilitate the transfer process, stringent
manufacturing and regulatory standards to ensure that the
transferred product is safe and effective and is scalable [36].
International agencies such as WHO, PATH, GAVI, Nether-
lands Vaccine Institute, Bill & Melinda Gates Foundation, CBER,
CDC Atlanta and national regulatory agencies played a
signiﬁcant role as partners for these technology transfers.
The case studies of pentavalent supplies, development of
meningococcal conjugate A vaccine at <50 cents/dose and
development of pandemic inﬂuenza vaccines highlight the
importance of technology transfers and the capacity of
DCVMN to undertake such successful technology transfers.
These technology transfers and partnerships further helped in
building the capacity of developing country manufacturers in
undertaking the development of sophisticated vaccines [37].
Table 3 highlights the products in development, suggesting that
in the next 5 years DCVMN will see the launch of innovative
vaccines such as those against rotavirus, pneumococci, HPV
and cholera, and vaccines against neglected diseases including
dengue fever and Leishmania diseases. The products in the
pipelines also reﬂect the merits of innovative access models
based on push and/or pull mechanisms, such as advanced
market commitment for pneumococcal conjugate vaccines.
These vaccines will be important for DoV initiatives as
rotavirus and pneumonia kill around 500 000 and 800 000
children, respectively, in developing countries each year. The
rotavirus and pneumonia vaccines from DCVMN members are
expected to bring down the prices of these vaccines globally.
The future offers new opportunities for building vaccine
capacities in developing countries, product development
partnerships, joint ventures and best practices for quality
control and guarantee of vaccines, leading to greater coverage.
To seize these opportunities the vaccine industry in developing
countries will also need to demonstrate continued success in
addressing the challenges affecting regulatory approval, man-
ufacturing, intellectual property regimens, ﬁnancing and, most
importantly demand predictability [38].
Newer vaccines in DoV offer opportunities to improve
public health. However, to realize their beneﬁts in developing
countries, DCVMN expects support from international agen-
cies in terms of funding, advocacy, strengthening national
agencies in making evidence-based decisions on introduction of
vaccines and enhancing the operational components of vaccine
supplies including storage and supply chains [39]. The DoV also
poses an important question of whether the existing ﬁnancing
mechanisms will sufﬁce to maintain coverage at current levels
for existing vaccines while supporting the introduction of
newer vaccines. It is estimated that by 2030 there may be as
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many as 20 vaccines in routine use whose applications will cost
the world as much as US$ 20 billion a year, which is far in
excess of the US$ 1–2 billion a year that is currently available
[4]. There are similar questions on DCVMN business models
to deliver affordable vaccines on a sustainable basis. In a recent
study on emerging vaccine manufacturers performed for
GAVI, it was suggested that emerging vaccine manufacturers
who are prepared to develop innovative products and license
these products for global markets will have better chances of
sustaining the future markets [9]. Many manufacturers in
DCVMN are taking signiﬁcant steps in investing or upgrading
their manufacturing capacities, improving their quality systems
and most importantly becoming partners in international
initiatives for the development of sophisticated vaccines [10].
DCVMN expects that international models of partnerships,
synergies, political will, efﬁcient policies that support the latest
manufacturing capabilities, supplies, access and support to
research and development innovations will maximize the
beneﬁts of immunization. In summary, DCVMN offers the right
blend of public and private companies to deliver affordable
vaccines and will have an important role to play in meeting the
future immunization targets of global healthcare.
Conclusion
The review showcases the growth, potential and achievements
of DCVMN in the global vaccination landscape. The review
further highlights the aspirations of DCVMN to undertake the
development of innovative vaccines. DCVMN expects new
approaches, policies to enhance capabilities, better and
innovative business models, collaborations with international
ﬁrms, improved intellectual property protection regimens, etc.
It is important to realize that success in biopharmaceutical
innovation is about the potential to adapt, scientiﬁcally, globally
and nationally in relation to the broader global pipeline of
vaccines. DCVMN is observing technological upgrading of
existing manufacturers leading to more competitive vaccines
for the generic market and at the same time is improving
capabilities when it comes to development of newer vaccines
at lower development costs. In this respect, DCVMN, in terms
of greater economies of scale and scope of capabilities, appears
to be in an advantageous position to undertake the DoV
initiatives and goals.
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